MedTrace Logo

Rollover Study From EXG-US-01

NCT05868499 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-07-12

No results posted yet for this study

Summary

This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).

Conditions

  • Telomere Biology Disorders With Bone Marrow Failure

Interventions

BIOLOGICAL

EXG34217

Single infusion

Sponsors & Collaborators

  • Elixirgen Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Kasiani Myers, MD · Cincinnati Children Hospital Medical Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2027-01-30
Completion
2027-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05868499 on ClinicalTrials.gov